REGENXBIO Quarterly Balance Sheet
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REGENXBIO financial position
As of Jun 30, 2026, REGENXBIO reported total assets of $386.6 million, down 33.5% from a year earlier against total liabilities of $314.9 million. Shareholders' equity stood at $71.8 million, or 18.6% of assets. The company held $36.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.86, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
REGENXBIO balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 36.49M | 15.23M | 34.47M | 58.80M | 79.56M | 130.10M | 57.53M | 56.62M | 57.77M | 112.97M | 34.52M | 53.05M |
| Short-Term Investments | 69.03M | 135.26M | 195.60M | 215.40M | 243.74M | 137.76M | 177.16M | 198.84M | 232.59M | 225.73M | 240.74M | 248.84M |
| Receivables | 106.75M | 10.04M | 26.38M | 25.35M | 20.20M | 18.19M | 20.47M | 23.60M | 22.81M | 15.83M | 24.79M | 28.04M |
| Total Current Assets | 236.16M | 186.52M | 281.28M | 331.97M | 373.75M | 313.24M | 278.00M | 313.40M | 346.68M | 395.42M | 334.97M | 365.84M |
| Property, Plant & Equipment | 98.45M | 101.87M | 104.86M | 107.52M | 111.02M | 114.50M | 117.59M | 120.55M | 123.97M | 127.66M | 132.10M | 135.53M |
| Long-Term Investments | — | — | 10.79M | 27.84M | 40.30M | 4.86M | 10.18M | 23.11M | 36.94M | 41.81M | 38.87M | 62.64M |
| Total Assets | 386.62M | 341.89M | 453.03M | 525.20M | 581.03M | 490.93M | 465.99M | 519.11M | 569.38M | 629.22M | 573.97M | 633.79M |
| Accounts Payable | 15.55M | 21.21M | 21.36M | 22.27M | 21.66M | 19.04M | 22.80M | 19.52M | 16.36M | 31.36M | 22.79M | 21.86M |
| Total Current Liabilities | 82.62M | 71.11M | 118.09M | 124.57M | 119.54M | 106.73M | 103.19M | 102.72M | 98.27M | 110.18M | 130.27M | 127.35M |
| Total Liabilities | 314.85M | 320.81M | 350.30M | 363.75M | 367.35M | 216.73M | 206.34M | 217.70M | 221.11M | 238.55M | 262.23M | 270.69M |
| Shareholders' Equity | 71.77M | 21.08M | 102.73M | 161.45M | 213.68M | 274.20M | 259.65M | 301.42M | 348.27M | 390.67M | 311.74M | 363.10M |
| Retained Earnings | -1.19B | -1.22B | -1.13B | -1.06B | -996.94M | -926.07M | -932.15M | -880.96M | -821.37M | -768.38M | -705.05M | -642.16M |
| Net Cash (Debt) | 105.52M | 150.49M | 230.07M | 274.20M | 323.30M | 267.87M | 234.69M | 255.46M | 290.36M | 338.70M | 275.26M | 301.89M |
| Shares Outstanding | 54.16M | 51.62M | 50.89M | 50.62M | 50.39M | 50.12M | 49.55M | 49.53M | 49.32M | 49.04M | 44.05M | 43.99M |
This table shows 12 quarterly periods of REGENXBIO's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RGNX's reporting calendar. What is a balance sheet?